GlassScriptPhysician profile
John J Sassano
NPI 1164410650
$4,062.46
in general payments reported to CMS, 2019-2025
37 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $56.40 · 2021: $70.53 · 2022: $1,765 · 2024: $452 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,541.11 | 2022 | |
| Abbvie INC. | $408.47 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $278.95 | 2019-2025 | Relistor |
| Novartis Pharmaceuticals Corporation | $248.14 | 2024-2025 | |
| Protega Pharmaceutials INC | $225.56 | 2025 | Roxybond |
| Nevro Corp. | $144.63 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.67 | 2024-2025 | Hyqvia |
| Pfizer INC. | $117.28 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $104.81 | 2019-2024 | |
| Collegium Pharmaceutical, INC. | $95.27 | 2019-2024 | Xtampza |
| Argenx US, INC. | $67.44 | 2025 | Vyvgart Hytrulo |
| Eisai INC. | $66.79 | 2024-2025 | |
| Novo Nordisk INC | $43.65 | 2019-2021 | |
| Grt US Holding, INC. | $42.19 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $39.54 | 2024 | Rexulti |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $39.32 | 2024-2025 | |
| Medtronic, INC. | $37.22 | 2025 | Inceptiv, Intellis Adaptivestim |
| Hikma Pharmaceuticals USA | $36.34 | 2022 | |
| Idorsia Pharmaceuticals US INC | $32.50 | 2024 | Quviviq |
| Lundbeck LLC | $32.20 | 2024-2025 | Vyepti |
| Biogen, INC. | $27.98 | 2025 | Leqembi |
| Foundation Medicine, INC. | $26.44 | 2020 | |
| Averitas Pharma INC. | $25.87 | 2025 | Qutenza |
| Catalyst Pharmaceuticals, INC. | $23.80 | 2024 | |
| Genentech USA, INC. | $20.92 | 2025 | Ocrevus Zunovo |
| Medtronic Vascular, INC. | $20.50 | 2019 | |
| Lilly USA, LLC | $19.96 | 2025 | Amyvid, Kisunla |
| Amneal Pharmaceuticals LLC | $19.43 | 2025 | Crexont |
| Relievant Medsystems, INC. | $18.83 | 2022 | |
| Alexion Pharmaceuticals, INC. | $18.77 | 2024 | Ultomiris |
| Janssen Biotech, INC. | $17.89 | 2025 | |
| Daiichi Sankyo INC. | $17.64 | 2019 | |
| Allergan, INC. | $16.31 | 2022 | |
| Boston Scientific Corporation | $15.26 | 2025 | Vercise |
| Abbott Laboratories | $15.26 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.89 | 2019 | |
| Biodelivery Sciences International, INC. | $11.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sassano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.